Some people breeze through their 70s with the vitality of someone decades younger, while others visibly decline. Ditto for their organs. Time and genetics explain some of this wear and tear, but does ...

More than 300 mutations in PSEN1 have been catalogued, but none are quite like the one Bart De Strooper and colleagues at the Flanders Institute for Biotechnology in Leuven, Belgium, reported on ...

Whether a person eats a cookie or devours the whole box could come down to the mood of microglia in their hypothalamus. Blocking activation of the region’s NLRP3 inflammasome could keep excessive ...

Antisense oligonucleotides have emerged as a promising approach for treating neurodegenerative disease. They can dial down toxic proteins or help restore functional ones, and have been approved for ...

Back in mid-June, Alzforum reported on how the AD research field was being buffeted by cuts in funding to the National Institutes of Health (Jun 2025 news; Jun 2025 news). At the time, scientists felt ...

CagA disrupts bacterial biofilms. It also prevents Aβ and α-synuclein from forming fibrils. Scientists will test CagA in AD and PD mouse models to assess its therapeutic potential. Scientists estimate ...

Austria’s beautiful capital city of Vienna hosted the 19th International Conference on Alzheimer’s and Parkinson’s diseases, which drew a record 5,554 attendees from 76 countries. From April 1 to 5, ...

At the 19th AD/PD conference, Alzforum reporters wrote 15 summaries of findings across both diseases. From a step toward finally having an α-synuclein PET tracer to a major focus on Trem2 as a drug ...

As the baby boom generation reaches its hopefully golden years, scientists have been projecting a doubling of dementia cases in the U.S. by 2050, alarming health care agencies, the public, and health ...

Alzheimer’s may be, at least in part, a disease of the immune system. Evidence supporting this comes from the study of genetics, infectious diseases, and the molecular machinations of the innate and ...

This letter was prompted by your recent perspective paper and the responses it provoked in an Alzforum discussion. Generally, my comments are offered with the intellectual humility required when ...

While anti-tau antibodies are beginning to look promising (see previous story), small molecules that modify tau proteins haven’t yet fared well in clinical trials. At the 16th Clinical Trials on ...